ASCCP Committee Opinion: Adjuvant Human Papillomavirus Vaccine for Patients Undergoing Treatment for Cervical Intraepithelial Neoplasia

Kathryn E. Sharpless; Jenna Z. Marcus; Lindsay M. Kuroki; Amy L. Wiser; Lisa Flowers

doi:10.1097/LGT.0000000000000703

Back

ASCCP Committee Opinion: Adjuvant Human Papillomavirus Vaccine for Patients Undergoing Treatment for Cervical Intraepithelial Neoplasia

Journal article

Open access

Peer reviewed

ASCCP Committee Opinion: Adjuvant Human Papillomavirus Vaccine for Patients Undergoing Treatment for Cervical Intraepithelial Neoplasia

Kathryn E. Sharpless, Jenna Z. Marcus, Lindsay M. Kuroki, Amy L. Wiser and Lisa Flowers

Journal of lower genital tract disease, Vol.27(1), pp.93-96

01/01/2023

DOI: 10.1097/LGT.0000000000000703

PMID: 36538783

Files and links (1)

url

https://doi.org/10.1097/LGT.0000000000000703View

Published (Version of record) Open Access

Abstract

Objectives Individuals treated for cervical intraepithelial neoplasia grade 2 or worse (CIN2+) are at long-term risk of persistent or recurrent disease despite treatment. This committee opinion aims to summarize and provide evidence-based recommendations for adjuvant human papillomavirus (HPV) vaccination based on available, published literature. Methods A task force from the ASCCP Practice Committee reviewed current Centers for Disease Control and Prevention (CDC) guidelines and previously published literature about the role of adjuvant HPV vaccination in previously unvaccinated individuals undergoing treatment for CIN2+ and other HPV-related diseases. Results Current CDC guidelines recommend routine or catch-up HPV vaccination for individuals aged 9 to 26 years, and shared decision making regarding vaccination for individuals aged 27 to 45 years. Multiple published studies suggest a possible benefit for adjuvant HPV vaccination in previously unvaccinated individuals undergoing treatment for CIN2+. Conclusions The American Society for Colposcopy and Cervical Pathology recommends adherence to current CDC recommendations for vaccination of individuals aged 9 to 26 years and consideration of the possible benefit of adjuvant HPV vaccination during shared decision making for previously unvaccinated individuals aged 27 to 45 years who are undergoing treatment for CIN2+.

American Society for Colposcopy and Cervical Pathology

cervical intraepithelial neoplasia

dysplasia

human papillomavirus vaccine

loop electrocautery excision procedure

treatment

Details

Title: Subtitle: ASCCP Committee Opinion: Adjuvant Human Papillomavirus Vaccine for Patients Undergoing Treatment for Cervical Intraepithelial Neoplasia
Creators: Kathryn E. Sharpless - Maine Medical Center
Jenna Z. Marcus - Northwestern University
Lindsay M. Kuroki - Washington University in St. Louis
Amy L. Wiser - Cascade (United States)
Lisa Flowers - Emory University
Resource Type: Journal article
Publication Details: Journal of lower genital tract disease, Vol.27(1), pp.93-96
DOI: 10.1097/LGT.0000000000000703
PMID: 36538783
NLM abbreviation: J Low Genit Tract Dis
ISSN: 1089-2591
eISSN: 1526-0976
Number of pages: 4
Grant note: 20515215; P50CA244431 / Doris Duke Charitable Foundation (http://data.elsevier.com/vocabulary/SciValFunders/100000862) Doris Duke Charitable Foundation (http://data.elsevier.com/vocabulary/SciValFunders/100000862)
Language: English
Date published: 01/01/2023
Academic Unit: Family and Community Medicine
Record Identifier: 9985134035202771

Metrics

1 Record Views